Found 1 Presentation For Request "497p"
497P - Investigating the potential relationship between KMT2C/KMT2D mutations and immune checkpoint inhibitor (ICI) in colorectal cancer (CRC)
- Chengli Miao (Beijing, China)
Abstract
Background
Methods
CRC data from our cohort (N=2,824) and DFCI (Cell Reports 2016) cohort (N=619) were used to analyze MSI status. CRC Data from MSKCC ICI (Nat Genet 2019) cohort (N=110) were used to evaluate the tumor mutation burden (TMB) and overall survival (OS). Characteristics compared between
Results
In our cohort, MSI-H was observed in 49% (32/65) of
Conclusions
In present study, we found KMT2C/2D mutations were tightly associated with MSI-H and higher TMB. The CRC patients with KMT2C/2D mutations could benefit from ICI therapy. Further prospective studies are warranted to comprehensively consider the mutations of KMT2C/2D, MSI-H and TMB, all of which may contribute to ICI clinical benefit.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
X. Zhang, T. Ma, X. Zhang, H. Zhu: Full/Part-time employment: Genetron Health (Beijing) Technology, Co. Ltd. All other authors have declared no conflicts of interest.